GSK vs BMY
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 18, 2026
GSK
BMY
Investment Advisor Scores
BMY
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | BMY | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 21.5517 | 9.3023 | BMY |
| PEG Ratio | 19.4203 | 1.5256 | BMY |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 1.5% | 2.6% | BMY |
| Earnings Growth | 8.4% | 9.2% | BMY |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 58.9/100 | 68.5/100 | BMY |
| Profit Margin | 17.8% | 15.0% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | BUY | BMY |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
DistributionPrice near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 48
BMY
MarkupPrice above SMA50, rising 50-day trend (2.4% over 20 days), RSI 71
Fundamentals Snapshot
| Metric | GSK | BMY |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.0 | 10.1 |
| Trailing P/E | 16.4 | 14.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.3% |
| EPS | 3.15 | 4.54 |
| Dividend Yield | 0.04% | 0.04% |